XGEVA Improves Metastasis-Free Survival In Castrate-Resistant Prostate Cancer
Cancer Care Cost To Jump by 27 Percent In a Decade, Reaching $158 Billion in 2020
Lilly Suspends Phase III Trial Of Tasisulam in Melanoma
Genomic Health Presents Meta-Analyses of Oncotype DX
In Phase II Study, NKTR-102 Shows Objective Response
Iniparib Plus Chemo Shows Benefit In Phase II Study
ColoPrint Improves Prognosis In Stage II and III Colon Cancer
Test May Identify Predictors For Recurrence Post-Surgery
Tissue of Origin Test Consistent With Diagnosis In Blinded Validation Study
Clinical Trials Approved By NCI CTEP Last Month
FDA Approves SNDA For Gardasil For Anal Cancer And Precancerous Lesions
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ
